• The acquisition will strengthen Stryker’s healthcare IT offering and wirelessly connected medical device portfolio.
• Stryker is a publicly traded company listed on the New York Stock Exchange under the ticker symbol SYK.
Portage, Michigan, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK), announced that it has completed the previously announced acquisition of care.ai, a privately held company specializing in delivering AI-assisted virtual care workflows, smart room technology and ambient intelligence solutions.
“We welcome the care.ai team to Stryker and look forward to working together to accelerate our digital vision to provide customers with real-time, smart and connected decision-making tools that can enhance the lives of caregivers and their patients,” stated Andy Pierce, Group President, MedSurg and Neurotechnology, Stryker.
The acquisition will strengthen Stryker’s growing healthcare IT offering and wirelessly connected medical device portfolio.
About Stryker
Stryker is a global leader in medical technologies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in MedSurg, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 150 million patients annually. More information is available at www.stryker.com.
Media contact:
Meghan Menz
Sr. Director, Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$364.27 |
| Daily Change: | 2.90 0.80 |
| Daily Volume: | 287,397 |
| Market Cap: | US$138.810B |
September 11, 2024 August 22, 2024 August 12, 2024 August 06, 2024 July 31, 2024 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
